



Update Summary

Entity name

MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED

Announcement Type

Update to previous announcement

Date of this announcement

Thursday December 17, 2020

Reason for update to a previous announcement

Updated minimum acceptance value to A500 dollars. Eligible Shareholders who wish to acquire Shares under the SPP must apply for a minimum amount of A500 dollars and thereafter for any amount of Shares under the Offer up to a maximum value of A30,000 dollars.

Refer to next page for full details of the announcement

Part 1 - Entity and announcement details

1.1 Name of +Entity

MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

1.2 Registered Number Type

ABN

Registration Number

14106340667

1.3 ASX issuer code

MVP

1.4 The announcement is☒ Update/amendment to previous announcement**1.4a Reason for update to a previous announcement**

Updated minimum acceptance value to A500 dollars. Eligible Shareholders who wish to acquire Shares under the SPP must apply for a minimum amount of A500 dollars and thereafter for any amount of Shares under the Offer up to a maximum value of A30,000 dollars.

1.4b Date of previous announcement(s) to this update

Monday December 14, 2020

1.5 Date of this announcement

Thursday December 17, 2020

1.6 The Proposed issue is:

- ☒ An offer of +securities under a +securities purchase plan
- ☒ A placement or other type of issue



Part 4 - Details of proposed offer under securities purchase plan

Part 4A - Conditions

4A.1 - Are any of the following approvals required for the offer of +securities under the +securities purchase plan issue to be unconditional?

- +Security holder approval
- Court approval
- Lodgement of court order with +ASIC
- ACCC approval
- FIRB approval
- Another approval/condition external to the entity

☒ No

Part 4B - Offer details

Class or classes of +securities that will participate in the proposed issue and class or classes of +securities proposed to be issued

ASX +security code and description

MVP : ORDINARY FULLY PAID

Will the proposed issue of this +security include an offer of attaching +securities?

☒ No

Details of +securities proposed to be issued

ASX +security code and description

MVP : ORDINARY FULLY PAID

Maximum total number of those +securities that could be issued if all offers under the +securities purchase plan are accepted

769,230

Will the offer be conditional on applications for a minimum number of +securities being received or a minimum amount being raised (i.e. a minimum subscription condition)?

☒ No

Will the offer be conditional on applications for a maximum number of +securities being received or a maximum amount being raised (i.e. a maximum subscription condition)?

☒ No



Will individual security holders be required to accept the offer for a minimum number or value of +securities (i.e. a minimum acceptance condition)?

☒ Yes

Is the minimum acceptance unit based or dollar based?

☒ Dollar based (\$)

Please enter the minimum acceptance value

\$ 500

Will individual security holders be limited to accepting the offer for a maximum number or value of +securities (i.e. a maximum acceptance condition)?

☒ Yes

Is the maximum acceptance unit based or dollar based?

☒ Dollar based (\$)

Please enter the maximum acceptance value

\$ 30,000

Describe all the applicable parcels available for this offer in number of securities or dollar value

Eligible Shareholders who wish to acquire Shares under the SPP must apply for a minimum amount of A\$500 and thereafter for any amount of Shares under the Offer up to a maximum value of A\$30,000.

Reason for the update of 'Maximum Number of +securities proposed to be issued'

Offer price details

Has the offer price been determined?

☒ Yes

In what currency will the offer be made?

AUD - Australian Dollar

What is the offer price per +security?

AUD 6.50000

Oversubscription & Scale back details

Will a scale back be applied if the offer is over-subscribed?

☒ Yes

Describe the scale back arrangements

The SPP will initially be capped at \$5m. However, the Board reserves the right in its absolute discretion to accept applications from eligible shareholders in excess of \$5m or to scale back applications (on a pro rata basis) if necessary. In the event of a scale back, eligible shareholders may not receive the full number of shares applied for under the SPP and the difference in any application monies will be refunded to them (without interest) following the issue of Shares under the SPP.

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?

☒ Yes



Part 4C - Timetable

4C.1 Date of announcement of +security purchase plan

Monday December 14, 2020

4C.2 +Record date

Friday December 11, 2020

4C.3 Date on which offer documents will be made available to investors

Friday December 18, 2020

4C.4 Offer open date

Friday December 18, 2020

4C.5 Offer closing date

Monday January 18, 2021

4C.6 Announcement of results

Thursday January 21, 2021

4C.7 +Issue date

Wednesday January 27, 2021

Part 4D - Listing Rule requirements

4D.1 Does the offer under the +securities purchase plan meet all of the requirements of listing rule 7.2 exception 5 or do you have a waiver from those requirements?

☒ Yes

Part 4E - Fees and expenses

4E.1 Will there be a lead manager or broker to the proposed offer?

☒ No

4E.2 Is the proposed offer to be underwritten?

☒ No



4E.3 Will brokers who lodge acceptances or renunciations on behalf of eligible +security holders be paid a handling fee or commission?

☒ No

4E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed offer

Fees and costs incurred by MVP in connection with the SPP include share registry fees, settlement fees and legal fees

Part 4F - Further Information

4F.01 The purpose(s) for which the entity intends to use the cash raised by the proposed issue

To principally fund the acceleration of Pentrox EU's commercial expansion through operational investments in the EU and Australia and completion of clinical studies. Refer to slide 14 of the investor presentation released on 14 Dec 2020.

4F.1 Will the entity be changing its dividend/distribution policy if the proposed offer is successful?

☒ No

4F.2 Countries in which the entity has +security holders who will not be eligible to accept the proposed offer

All countries other than Australia and New Zealand

4F.3 URL on the entity's website where investors can download information about the proposed offer

<https://medicaldev.com/investors-media/>

4F.4 Any other information the entity wishes to provide about the proposed offer

No



Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

7A.1 - Are any of the following approvals required for the placement or other type of issue?

- +Security holder approval
- Court approval
- Lodgement of court order with +ASIC
- ACCC approval
- FIRB approval
- Another approval/condition external to the entity

☒ No

Part 7B - Issue details

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?

☒ Existing class

Will the proposed issue of this +security include an offer of attaching +securities?

☒ No

Details of +securities proposed to be issued

ASX +security code and description

MVP : ORDINARY FULLY PAID

Number of +securities proposed to be issued

3,846,154

Reason for the update of 'Maximum Number of +securities proposed to be issued'

Offer price details

Are the +securities proposed to be issued being issued for a cash consideration?

☒ Yes

In what currency is the cash consideration being paid?

AUD - Australian Dollar

What is the issue price per +security?

AUD 6.50000



Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?

☒ Yes

Part 7C - Timetable

7C.1 Proposed +issue date

Friday December 18, 2020

Part 7D - Listing Rule requirements

7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1?

☒ No

7D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

☒ Yes

7D.1b (i) How many +securities are proposed to be issued without security holder approval using the entity's 15% placement capacity under listing rule 7.1?

3,846,154

7D.1c Are any of the +securities proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?

☒ No

7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue?

☒ Yes

7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?

☒ No

7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?

☒ No

Part 7E - Fees and expenses

7E.1 Will there be a lead manager or broker to the proposed issue?

☒ Yes

7E.1a Who is the lead manager/broker?

The lead manager to the SPP is Bell Potter Securities Limited (Bell Potter).



7E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?

In respect of the placement, Bell Potter will be paid in total a fee of 2% of the proceeds received by the Company under the placement (solely for lead managing the institutional placement).
Bell Potter will also be reimbursed for customary expenses.

7E.2 Is the proposed issue to be underwritten?

☒ No

7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue

Fees and costs incurred by MVP in connection with the placement include share registry fees, settlement fees and legal fees.

Part 7F - Further Information**7F.01 The purpose(s) for which the entity is issuing the securities**

To principally fund the acceleration of Pentrox EU's commercial expansion through operational investments in the EU and Australia and completion of clinical studies. Refer to slide 14 of the investor presentation released on 14 Dec 2020.

7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?

☒ No

7F.2 Any other information the entity wishes to provide about the proposed issue

For further details of the placement please refer to the announcement released to ASX by the Company on Monday, 14 December 2020